Sarepta Therapeutics

Will Sarepta reverse after steep drop?
Will Sarepta reverse after steep drop?
Yahoo/OptionMonster
Sarepta Therapeutics
Flag link:
3 Key FDA Decisions Expected in February
3 Key FDA Decisions Expected in February
24/7 Wall St
FDA
Vertex Pharmaceuticals
Kalydeco
Regulus
RG-101
Sarepta Therapeutics
eteplirsen
Flag link:
Why the FDA shouldn’t bow to parental pressure over Duchenne drug
Why the FDA shouldn’t bow to parental pressure over Duchenne drug
Stat
FDA
Duchenne Muscular Dystrophy
drug approvals
Biomarin
Sarepta Therapeutics
Flag link:
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Yahoo/Benzinga
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area
FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area
Yahoo
FDA
advisory panels
Duchenne Muscular Dystrophy
eteplirsen
Sarepta Therapeutics
Flag link:
Four big problems with the FDA’s analysis of Sarepta’s Duchenne drug data
Four big problems with the FDA’s analysis of Sarepta’s Duchenne drug data
Bizjournals.com
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
​Duchenne mom: FDA is ‘looking for reasons to deny’ Sarepta’s drug
​Duchenne mom: FDA is ‘looking for reasons to deny’ Sarepta’s drug
Bizjournals.com
FDA
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
Sarepta Therapeutics' Eteplirsen Likely To Get A Conditional Approval By FDA
Sarepta Therapeutics' Eteplirsen Likely To Get A Conditional Approval By FDA
Seeking Alpha
FDA
Duchenne Muscular Dystrophy
Sarepta Therapeutics
eteplirsen
Flag link:
6 BioHealth Movers That Now Cannot Be Ignored
6 BioHealth Movers That Now Cannot Be Ignored
24/7 Wall St
Clovis Oncology
KaloBios
Celladon
Sarepta Therapeutics
Zafgen
Valeant Pharmaceuticals
Flag link:
Duchenne moms say FDA documents ‘widen the divide’ between drugs by BioMarin, Sarepta
Duchenne moms say FDA documents ‘widen the divide’ between drugs by BioMarin, Sarepta
Bizjournals.com
Duchenne Muscular Dystrophy
FDA
eterplirsen
drisapersen
Biomarin
Sarepta Therapeutics
Flag link:
4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming
4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming
24/7 Wall St
Pfizer
Sarepta Therapeutics
PTC Therapeutics
Amag Pharmaceuticals
Flag link:
Experts say Sarepta has a clear edge over BioMarin in Duchenne drug battle
Experts say Sarepta has a clear edge over BioMarin in Duchenne drug battle
Bizjournals.com
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
Flag link:
FDA ‘Weirdness?’ Separate meetings for BioMarin and Sarepta DMD drugs
FDA ‘Weirdness?’ Separate meetings for BioMarin and Sarepta DMD drugs
Pharmalot
FDA
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
Flag link:
​Sarepta’s competitor on Duchenne drug could get a two-month head start on sales
​Sarepta’s competitor on Duchenne drug could get a two-month head start on sales
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biomarin
eteplirsen
drisapersen
Flag link:
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Motley Fool
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
Flag link:
Sarepta's Less-Than-Perfect Data
Sarepta's Less-Than-Perfect Data
Motley Fool
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Sarepta gets creative in bolstering its case for quick eteplirsen approval
Sarepta gets creative in bolstering its case for quick eteplirsen approval
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
​Redemption for the drug biz could come next week from Cambridge-based Sarepta
​Redemption for the drug biz could come next week from Cambridge-based Sarepta
Bizjournals.com
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
The Market Swooned, but Sarepta Therapeutics Soared in August
The Market Swooned, but Sarepta Therapeutics Soared in August
Motley Fool
Sarepta Therapeutics
eteplirsen
Flag link:
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Fierce Biotech
Sarepta Therapeutics
priority review
Duchenne Muscular Dystrophy
FDA
eteplirsen
drisapersen
Biomarin
Flag link:

Pages